Table 4 Results from a systematic review of studies included in the review
Source | Country-period | Sites (design) | Study population | Nr. of individuals with IgG onc. Abs./ in study | Patients with tumors | Age (y, median/ *mean); % female | Abs studied | Onc. Abs. studied | Analytic method | Psychiatric reference standard (ICD-10, DSM-IV and IIIR) | Prevalence psychiatric symptoms in study/onc. Ab. pos. Pat. | Psychiatric symptoms reported in onc. Ab. pos. Pat. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hammack et al. 1990 [25] | US (NY) -? | S (r) | PCD | 16/32 | 27/32 | ?; 50 | Anti-Purk. cell Abs | Anti-Purk. cell Abs | IIF | None | 28%/38% | Depr., psychosis |
Dalmau et al. 1992 [26] | US (NY) – 83-90 | 3 (r) | Hu-ass par. enc. myel./ sens neur. | 71/71 | 62/71 | 60; 55 | Hu | Hu | WB, Im.hi. | None | 21%/21% | Depr., anxiety, mem. Loss, hall. |
Peterson et al. 1992 [27] | US -? -91 | M (r) | Yo-pos pat | 55/55 | 52/55 | 61; 100 | Yo | Yo | WB, Im.hi. | None | 18%/18% | Emo. lab., mem. Def. |
Alamowitch et al. 1997 [28] | ? - 87-94 | S (r) | LE and SCLC | 8/16 | 16/16 | ?; 13 | Hu | Hu | Im.bl, Im.hi. | None | 88%/88% | Depr., anx., pers. ch, hall. |
Black et al. 1998 [29] | US (Roch) -? | S (c) | OCD pat | 0/13 | ? | 36; 46 | 14 | Yo, Hu, Ri, Amph | IIF | DSM-IIIR | 100%/− | - |
Voltz et al. 1999 [31] | US (NY) -? | S (r) | Testis cancer and PLE | 10/19 | 19/19 | ?; 0 | Ma2 | Ma2 | WB, Im.hi. | None | ?/40% | Anxiexy., depr., hall. |
Antoine et al. 1999 [30] | France - 72-96 | 1 (r) | Amphiphysin pos pa | 5/5 | 5/5 | 67; 40 | Amph. | Amph. | WB, Im.hi. | None | ?/20% | Anxiexy., depr., hall. |
Gultekin et al. 2000 [2] | US (NY) -? | S (r) | PLE | 30/50 | 48/50 | 55; 46 | 6 | Hu, Ma1, Ma2, CRMP-5/CV2 | Im.bl, Im.hi. | None | 42%/? | ? |
Yu et al. 2001 [32] | US (Minn) - 93-00 | 1 (r) | CRMP5 (CV2) pos patients | 116/116 | 105/116 | ?; 58 | CRMP-5/CV2 | CRMP-5/CV2 | Im.bl, IIF | None | 21%/21% | Pers ch., depr., psychosis |
Sillevis Smitt et al. 2002 [33] | Netherlands– 89 – 99 | S (r) | Hu-ass. par. enc.myel./ sensory neuronopathy | 73/73 | 62/73 | 66; 34 | Hu | Hu | WB, IIF | None | 2.7%/2.7% | Depr. |
Lawn et al. 2003 [34] | Us (Roch) 85–02 | S (r) | PLE | 10/24 | 24/24 | 61; 63 | 11 | Hu, Ri, Yo, Tr, CRMP-5/CV2, Amph | WB, IIF | None | 50/? | Depr., anxiety, pers. ch, hall. |
Overeem et al. 2004 [36] | US (AR) -? | S (r) | Ma2 ass. enc. | 6/6 | 6/6 | 49; 50 | Ma2 | Ma2 | Im. bl. | None | 50%/50% | Depr., pers. ch. |
Dalmau et al. 2004 [35] | US (Penn) -? | 2 (r) | Ma2-ass. enc. | 38/38 | 34/38 | ?; 32 | Ma1/Ma2 | Ma1/Ma2 | Im. bl. | None | 11%/11% | Nerv. br.down, loss of self-conf., panic attack |
Hoffman et al. 2008 [37] | Germany/England – 99-05 | 2 (r) | Anti-Ma1/Ma2 ass. PNS | 22/22 | 17/22 | 60; 36 | Ma1/Ma2 | Ma1/Ma2 | Im.bl., IIF. | None | 18% | OCS, pers. ch., aff. Symptoms |
McKeon et al. 2011 [38] | US (Minn, Ari, Flor) - 87-07 | 3 (r) | Yo-pos p | 83/83 | 73/83 | 60; 100 | Yo | Yo | IIF | None | 5%/5% | Pers. ch. |
Chiaie et al. 2012 [39] | Italy -? | S (c) | Psychiatric pat PCD pat Healthy controls | 11/48 22/22 0/52 | 0/48 22/22 0/52 | 36*; 13 56*; 68 44*; 50 | 5 | Anti-Purk. cell Abs | IIF | DSM-IV | 100%/100% | Schizophrenia, bipolar disord., OCD |
Saraya et al. 2013 [40] | Thailand. - 10-12 | 17 (p) | Autoimmune encephalitis | 9/103 | 6/103 | ?; 68 | 20 | Hu, Ri, Yo, Tr, CRMP-5/CV2, Amph, SOX1 | Im.bl, IIF | None | ?/33% | Psychosis, Beh ch. |
Dahm et al. 2014 [41] | Germany – 05-11 | M (c) | Healthy Schizophrenia Aff. disord. Bord. pers. disord. | 47/1703 38/1378 8/310 0/42 | ? | ?; 40 | 24 | Amph, Ma1, Ma2, CRMP-5/CV2, Tr, Hu, Rec, Ri, Yo | IIF | DSM-IV | 100%/100% | - |
Moon et al. 2014 [47] | South Korea– 12-14 | S (r) | Non-stiff amphiphysin syndrome | 20/20 | 7/20 | 58*; 40 | 12 | Amph., Hu, Yo, Ri, Ma2, CRMP-5. | Im.bl. | None | 25%/25% | Irritability, psychosis |
Laadhar et al. 2015 [17] | Tunisia -? | S (c) | Psychiatric pat Healthy controls | 5/103 0/41 | 0/103 0/41 | 43*; 28 41*; 22 | ANNA, PCA1, ANA | Hu, Ri, Yo | WB, IIF | DSM-IV | 100%/100% | Schizophrenia, schizoaff. And bipolar disord. |
Haukanes et al. 2015 [43] | Norway -? | S (c) | ADHD pat Healthy controls | 0/169 0/56 | 0/169 0/56 | 33*; 50 35*; 55 | Yo, Amph, CRMP-5, Ma2, Ri, Hu | Yo, Amph, CRMP-5/CV2, Ma2, Ri, Hu | Im.bl, WB, IIF | DSM-IV | 100%/− | - |
Kruse et al. 2015 [44] | US (Roch)- 02–11 | S (r) | Psychiatric inpat Healthy controls | 1/213 0/173 | ? | ?;? | ? | Hu, Ri, SOX1, Yo, CRMP-5/CV2, Amph, Tr | Im.bl, IIF, ELISA | Chart review | 100%/100% | Pers ch, paranoia, agitation etc |
Endres et al. 2015 [42] | Germany – 06-13 | S (c) | Pat with psychotic synd. (CSF) | 5/142 (180) | 0/180 | 35*; 56 | 14 | Yo, Hu, Ri, CRMP-5/CV2, Ma1, Ma2, SOX1, Amph | Im.bl. | ? | 100%/100% | Schizophreniform or schizoaff. synd. |
Sæther et al. 2016 [46] | Norway – 04-06 | S (c) | Acutely admitted psychiatric inpat | 1/585 | ? | 41*; 51.8 | 15 | Yo, Amph, CRMP-5/CV2, Hu, Ri, Ma2, Rec | Im.bl, IIF | ICD-10 | 100%/100% | Paranoid psychosis |
Endres et al. 2016 [45] | Germany – 06 – 13 | S (c) | Pat with depressive synd. (CSF) | 0/63 (125) | ? | 53*; 48 | ? | Yo, Hu, Ri, CRMP-5/CV2, Ma1, Ma2, SOX1, Amph | Im.bl. | ? | 100%/− | - |
Hansen et al. 2016 [48] | Germany – 07-15 | S (r) | PLE: GAD65 Onconeur. abs | 0/11 11/11 | ? 1/11 | 41; 64 43; 73 | 22 | Ma1/2, Hu, Ri, Yo, SOX1, CRMP-5, Recoverin, Amph. | Im. hi., Im.bl. |  | 66%/73% | Depression |
Schwenkenbecher et al. 2016 [49] | Germany – 96-15 | S (r) | Hu-pos. Pat with PS | 18/18 | 16/18 | 61; 61 | Hu | Hu | Im.hi., im.bl. | None | ?/? | Aggressive-ness, anxiety |